Hematology

Latest News
September 12th 2025

Refined iRR6 Model Improves Risk Stratification in Intermediate-1 Myelofibrosis

September 10th 2025

COVID-19 Risk Remains High for Patients With Hematologic Malignancies

September 4th 2025

Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

August 31st 2025

Immune Profiling May Help Gauge Infection Risk in Patients With CLL

August 29th 2025

Gene Therapy Meaningfully Improves Quality of Life in Severe Sickle Cell Disease

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo
Video Interviews
View All
September 10th 2025

Navigating Cilta-Cel Sequencing in Multiple Myeloma: Surbhi Sidana, MD, MBBS

September 5th 2025

Value-Based Myeloma Care Amid Game-Changing Therapeutic Developments: Matias Sanchez, MD

September 2nd 2025

Rusfertide Poised to Transform Polycythemia Vera Care: Andrew Kuykendall, MD

August 28th 2025

Optimizing Multiple Myeloma Treatment as Therapy Costs Rise: Matias Sanchez, MD

August 27th 2025

MRD Testing Could Cut Costs, Refine Blood Cancer Care: Ravi Vij, MD, MBA

August 25th 2025

Insurance Delays Add Costs to CAR T-Cell Therapy: Ravi Vij, MD, MBA

August 21st 2025

CAR T and Bispecifics Pose Different Challenges in Blood Cancer Treatment: Ravi Vij, MD, MBA

August 18th 2025

Outpatient Models Boost Cost-Effectiveness of CAR T and Bispecific Therapy in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

August 15th 2025

Leveraging MRD Testing to Advance Value-Based Care in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

August 14th 2025

Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD

Podcasts
View All
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

May 5th 2018

Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News

March 10th 2018

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

December 14th 2017

Five Years of Reducing Overuse of Medical Services With Choosing Wisely

More News

Real-world outcomes of venetoclax treatment were similar to those seen in clinical trials in patients with chronic lymphocytic leukemia | Image Credit: tippapatt - stock.adobe.com
August 29th 2025

Real-World Data Support Safety, Efficacy of Venetoclax for CLL

Jared Kaltwasser
A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.
It was difficult to generate strong conclusions from the existing data due to the “sparse and heterogeneous” nature of the cardiovascular data reported in the trials. | Image credit: Tima - stock.adobe.com
August 27th 2025

Age, BTKi Use May Contribute to Cardiovascular Risk in CLL

Jared Kaltwasser
Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more comprehensive information is needed to draw strong conclusions.
The new research points to the potential of AP-1 and stromal interactions as promising targets to overcome resistance and improve outcomes in CLL. | Image credit: jarun011 - stock.adobe.com
August 26th 2025

AP-1 as a Therapeutic Focus in CLL

Kimberly Rath, PharmD
Novel 3D analysis reveals core tumor niches drive resistance through AP-1 signaling and stromal reprogramming.
SWIFT-seq was able to successfully capture CTCs in 90% of patients with MGUS, SMM, and MM. | Image credit: luchschenF - stock.adobe.com
August 23rd 2025

Novel Blood Test Could Transform Multiple Myeloma Diagnosis, Monitoring

Jared Kaltwasser
Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.
Overall, participants with CLL had significantly lower MLR values compared with the healthy donors. | Image credit: angellodeco - stock.adobe.com
August 22nd 2025

Monocyte-to-Lymphocyte Ratio Linked With Functional Status in CLL

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with healthy controls.
Whether KRd‐based quadruplets will redefine the frontline standard now hinges on proving they can deliver deeper, longer‐lasting remissions without compromising safety. | Image credit: Dzmitry - stock.adobe.com
August 21st 2025

Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone

Kimberly Rath, PharmD
Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.
Further research into the interplay between bone marrow, pulmonary vasculature, and cardiac function could help develop novel therapeutic strategies that could benefit both MPNs and cardiovascular disease. | Image credit: Tima - stock.adobe.com
August 21st 2025

MPNs May Increase Risk of Nonthrombotic Cardiovascular Conditions

Jared Kaltwasser
Patients with myeloproliferative neoplasms (MPNs) appear to be at a higher risk of heart failure and pulmonary hypertension, though more research into the links is needed.
When CLL treatment types were compared, BTKi recipients reported better social/family well-being than those under surveillance. In contrast, venetoclax recipients reported lower physical well-being than the surveillance group. | Image credit: Kay Abrahams - stock.adobe.com
August 21st 2025

Gender-Specific Approaches to CLL Care May Improve QOL Outcomes

Kimberly Rath, PharmD
Men fared better under surveillance, while women benefited more from targeted therapies for the treatment of chronic lymphocytic leukemia (CLL) in a new study.
Modern Medical Technologies | Image credit: Prostock-studio - stock.adobe.com
August 16th 2025

Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML

Laura Joszt, MA
Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
August 14th 2025

AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

Kimberly Rath, PharmD
A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.
Integrating CAR T-Cell Therapy and Bispecific Antibodies Into Hematologic Malignancy Care: Anita D’Souza, MD
August 11th 2025

Integrating CAR T-Cell Therapy and Bispecific Antibodies Into Hematologic Malignancy Care: Anita D’Souza, MD

Anita D’Souza, MD Alana Hippensteele, MA
Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are transforming multiple myeloma care, with earlier use, expanded community access, and outpatient delivery models offering opportunities to improve value, safety, and equity in treatment.
Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
August 8th 2025

QRISK3 Tool Predicts Thrombotic Events in ET, PV

Jared Kaltwasser
The QRISK3 assessment is designed for the general population, but it appears to also have utility in patients with essential thrombosis and polycythemia vera.
BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
August 7th 2025

New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

Jared Kaltwasser
Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Surbhi Sidana, MD, MBBS, Stanford University
August 7th 2025

Safety Should Always Be a Priority With CAR T for Multiple Myeloma: Surbhi Sidana, MD, MBBS

Maggie L. Shaw Surbhi Sidana, MD, MBBS
Cilta-cel’s mechanism of action allows it to penetrate challenging areas of multiple myeloma, providing deep and durable responses even in high-risk patients, explains Surbhi Sidana, MD, MBBS, Stanford University. Still, safety trade-offs should always be a consideration, she adds.
MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
July 31st 2025

Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

Maggie L. Shaw
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com
July 31st 2025

Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

AJMC Contributor
A cumulative review offers strong evidence that acalabrutinib has a low incidence of cardiac failure in both clinical trial and real-world settings.
Gloved hands holding ALL blocks | Image credit: Sviatlana - stock.adobe.com
July 30th 2025

Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

Laura Joszt, MA
Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.
Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com
July 29th 2025

Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

Jared Kaltwasser
Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.
Andrew Kuykendall, MD, Moffitt Cancer Center
July 29th 2025

Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD

Maggie L. Shaw Andrew Kuykendall, MD
Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.
The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com
July 29th 2025

Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

AJMC Contributor
A recent study suggests hemorrhagic events following essential thrombocythemia diagnosis are among the most significant predictors of early death.
Black, Hispanic, and Pacific Islander patients generally experienced worse OS compared with White patients, while Asian patients had similar outcomes. | Image credit: Colored Lights - stock.adobe.com
July 28th 2025

Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

Kimberly Rath, PharmD
A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.
Older regimens for CLL were frequently used in older patients and were associated with significantly shorter overall survival, the authors found. | image credit: Saiful52 - stock.adobe.com
July 28th 2025

Newer Agents Should Be Used in First Line for Older Patients With CLL

AJMC Contributor
New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.
Despite the benefits associated with adequate physical function in CLL, 70% of respondents said they had never received any physical activity advice from a doctor. | Image Credit: kieferpix - stock.adobe.com.jpg
July 27th 2025

Exercise Tied to Improved Symptoms, QOL in Patients With CLL

AJMC Contributor
While physical activity was linked with improved quality of life (QOL), the majority of patients are not given the recommendation from their doctor.
In a novel finding, the study pinpointed 2 independent risk factors for AF development in this population: elevated interleukin-1β and TET2 mutation. | Image credit: mdaros - stock.adobe.com
July 27th 2025

Study Identifies Potential Genetic Drivers, Targeted Treatments for AF in MPN

AJMC Contributor
The study found that atrial fibrillation (AF) significantly increases stroke and mortality risk in certain patients with myeloproliferative neoplasms (MPNs).
In chronic lymphocytic leukemia (CLL), TP53 has been an important subject of investigation since the early 1990s. | Image credit: MdBabul - stock.adobe.com
July 25th 2025

TP53 Mutations Remain Important Research Focus in Cancer

Jared Kaltwasser
TP53 mutations can have a significant impact on the prognosis of diseases like chronic lymphocytic leukemia, but their effect can vary based on numerous factors.
Adcetris packaging | Image: Pfizer
July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Mary Caffrey
Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).
David Nguyen, MD | Image Credit: Tufts Medicine
July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD
David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Amir Fathi, MD, Mass General
July 23rd 2025

Expertise Is Essential to Bispecific Access for Patients With Acute Leukemias: Amir Fathi, MD

Maggie L. Shaw Amir Fathi, MD
Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely administer and manage them.
Taken together, the findings suggest that the use of venetoclax following BTKi discontinuation is a feasible strategy that may help overcome toxicity-related challenges associated with long-term BTKi use. | Image credit: jarun011 - stock.adobe.com
July 23rd 2025

Venetoclax Consolidation a Feasible Strategy After BTKi in CLL

Jared Kaltwasser
Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.
Regarding survival, outcomes were similar to those seen in clinical trials of ruxolitinib for myelofibrosis. | Image credit: fotogurmespb - stock.adobe.com
July 18th 2025

Ruxolitinib Shows Sustained Clinical, QOL Benefits in MPN Real-World Data

Rose McNulty
The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.
12345678
...
29>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo